Please join the Elicio Therapeutics management team for a virtual key opinion leader (KOL) event to discuss complete radiographic and complete metabolic responses in patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy.

The event will feature insights from leading experts:

• Peter Hosein, M.D. – Professor of Clinical Medicine, Sylvester Comprehensive Cancer Center, University of Miami
• Zev Wainberg, M.D. – Professor of Medicine, UCLA, Co-Director of the UCLA GI Oncology Program

Christopher Haqq, M.D. Ph.D. Chief Medical Officer, Elicio Therapeutics will also review Elicio’s plans to evaluate ELI-002 7P in combination with checkpoint inhibition and standard therapy in metastatic pancreatic cancer in a Phase 1 study, which, if successful, could allow for a more rapid development pathway for ELI-002 7P.

A live question and answer session will follow the formal presentations.